Dept. Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta Barat, DKI Jakarta, Indonesia.
Adult Cardiac Surgery Division, Department of Surgery, Faculty of Medicine, Universitas Indonesia/National Cardiovascular Center Harapan Kita, Jakarta Barat, DKI Jakarta, Indonesia.
Glob Heart. 2024 Jan 11;19(1):4. doi: 10.5334/gh.1285. eCollection 2024.
Mitral valve repair (MVr) has been shown to achieve better outcomes than mitral valve replacement (MVR) in degenerative aetiology. However, that cannot be applied in rheumatic mitral valve disease. Therefore, this study aims to evaluate early and late clinical outcomes and mid-term survival in RHD compared to the non-RHD group and whether mitral valve repair is a better surgical approach in RHD patients.
Patients who underwent mitral valve surgery with or without coronary artery bypass grafting were included in this study. All patients were divided into the RHD and non-RHD group by the type of mitral surgery performed. Early and late outcomes were evaluated, and mid-term cumulative survival was reported.
A total of 1382 patients post MV surgeries were included. The 30-day mortality was significantly higher in the RHD group compared to the non-RHD group (8.7% vs. 4.4%, p = 0.003). There was no difference in 30-day mortality between repair and replacement in each respective group. During follow-up (12-54 months), all-cause mortality between RHD and non-RHD groups (16.7% vs. 16.2%) was not different. In the RHD group, the survival of MVr was 85.6% (95% CI 82.0%-88.5%), and MVR was 78.3% (95% CI 75.8%-80.6%), p-value log rank 0.26 However, in the non-RHD group, patients who underwent MVr had better survival than MVR, with cumulative survival of 81.7% (95% CI 72.3%-88.2%) vs. 71.1% (95% CI 56.3%-81.7%) p-value log rank 0.007.
Early mortality rate in rheumatic mitral valve surgery was higher than in non-rheumatic valve surgery. Although in rheumatic MV disease MV repair did not show a significant survival advantage over MV replacement, a trend towards more favourable survival in the repair group was observed.
在退行性病因中,二尖瓣修复(MVr)的效果优于二尖瓣置换(MVR)。然而,这一方法不适用于风湿性二尖瓣疾病。因此,本研究旨在评估风湿性心脏病(RHD)患者与非风湿性心脏病患者相比,在早期和晚期临床结果以及中期生存率方面的差异,以及二尖瓣修复是否是 RHD 患者更好的手术方法。
本研究纳入了接受二尖瓣手术(伴或不伴冠状动脉旁路移植术)的患者。所有患者根据所行二尖瓣手术类型分为 RHD 组和非 RHD 组。评估早期和晚期结果,并报告中期累积生存率。
共纳入 1382 例行 MV 手术的患者。RHD 组 30 天死亡率明显高于非 RHD 组(8.7% vs. 4.4%,p=0.003)。在每个亚组中,修复组和置换组之间 30 天死亡率无差异。在随访期间(12-54 个月),RHD 组和非 RHD 组的全因死亡率(16.7% vs. 16.2%)无差异。在 RHD 组,MVr 的生存率为 85.6%(95%CI82.0%-88.5%),MVR 为 78.3%(95%CI75.8%-80.6%),p 值对数秩检验为 0.26。然而,在非 RHD 组中,MVr 组的生存情况优于 MVR 组,累积生存率分别为 81.7%(95%CI72.3%-88.2%)和 71.1%(95%CI56.3%-81.7%),p 值对数秩检验为 0.007。
风湿性二尖瓣手术的早期死亡率高于非风湿性瓣膜手术。尽管在风湿性 MV 疾病中,二尖瓣修复并未显示出明显优于二尖瓣置换的生存优势,但修复组的生存情况有更有利的趋势。